By Associate Professor Nicola J Smith

Journal articles

Smith NJ; Milligan G, 2010, 'Allostery at G protein-coupled receptor homo- and heteromers: Uncharted pharmacological landscapes', Pharmacological Reviews, 62, pp. 701 - 725, http://dx.doi.org/10.1124/pr.110.002667

Schröder R; Janssen N; Schmidt J; Kebig A; Merten N; Hennen S; Müller A; Blättermann S; Mohr-Andrä M; Zahn S; Wenzel J; Smith NJ; Gomeza J; Drewke C; Milligan G; Mohr K; Kostenis E, 2010, 'Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements', Nature Biotechnology, 28, pp. 943 - 949, http://dx.doi.org/10.1038/nbt.1671

Milligan G; Stoddart LA; Smith NJ, 2009, 'Agonism and allosterism: The pharmacology of the free fatty acid receptors FFA2 and FFA3', British Journal of Pharmacology, 158, pp. 146 - 153, http://dx.doi.org/10.1111/j.1476-5381.2009.00421.x

Smith NJ; Stoddart LA; Devine NM; Jenkins L; Milligan G, 2009, 'The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1', Journal of Biological Chemistry, 284, pp. 17527 - 17539, http://dx.doi.org/10.1074/jbc.M109.012849

Stoddart LA; Smith NJ; Milligan G, 2008, 'International union of pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: Pharmacology and pathophysiological functions', Pharmacological Reviews, 60, pp. 405 - 417, http://dx.doi.org/10.1124/pr.108.00802

Stoddart LA; Smith NJ; Jenkins L; Brown AJ; Milligan G, 2008, 'Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids', Journal of Biological Chemistry, 283, pp. 32913 - 32924, http://dx.doi.org/10.1074/jbc.M805601200

Milligan G; Smith NJ, 2007, 'Allosteric modulation of heterodimeric G-protein-coupled receptors', Trends in Pharmacological Sciences, 28, pp. 615 - 620, http://dx.doi.org/10.1016/j.tips.2007.11.001

Smith NJ; Luttrell LM, 2006, 'Signal switching, crosstalk, and arrestin scaffolds: Novel G protein-coupled receptor signaling in cardiovascular disease', Hypertension, 48, pp. 173 - 179, http://dx.doi.org/10.1161/01.HYP.0000232641.84521.92

Chan HW; Smith NJ; Hannan RD; Thomas WG, 2006, 'Tackling the EGFR in pathological tissue remodelling', Pulmonary Pharmacology and Therapeutics, 19, pp. 74 - 78, http://dx.doi.org/10.1016/j.pupt.2005.04.005

Smith NJ; Chan HW; Osborne JE; Thomas WG; Hannan RD, 2004, 'Hijacking epidermal growth factor receptors by angiotensin II: New possibilities for understanding and treating cardiac hypertrophy', Cellular and Molecular Life Sciences, 61, pp. 2695 - 2703, http://dx.doi.org/10.1007/s00018-004-4244-3

Thomas WG; Qian H; Smith NJ, 2004, 'When 6 is 9: 'Uncoupled' AT1 receptors turn signalling on its head', Cellular and Molecular Life Sciences, 61, pp. 2687 - 2694, http://dx.doi.org/10.1007/s00018-004-4245-2

Devlin MG; Smith NJ; Ryan OM; Guida E; Sexton PM; Christopoulos A, 2004, 'Regulation of serotonin 5-HT 2C receptors by chronic ligand exposure', European Journal of Pharmacology, 498, pp. 59 - 69, http://dx.doi.org/10.1016/j.ejphar.2004.07.102

Smith NJ; Hannan RD; Thomas WG; Lew RA, 2003, 'AngiotensinII mediates cardiomyocyte hypertrophic growth pathways via MMP-dependent HB-EGF liberation', Letters in Peptide Science, 10, pp. 431 - 435, http://dx.doi.org/10.1007/BF02442574

Smith NJ; Hannan RD; Thomas WG; Lew RA, 2003, 'AngiotensinII mediates cardiomyocyte hypertrophic growth pathways via MMP-dependent HB-EGF liberation', International Journal of Peptide Research and Therapeutics, 10, pp. 431 - 435, http://dx.doi.org/10.1007/s10989-004-2398-3

Back to profile page